Virus News and Research

Latest Virus News and Research

Study first to document increase risk of herpes infection due to oral sex, particularly in young women

The first clinical study to document risk of acquiring herpes simplex virus type 1 infection based on sexual activity has linked oral sex and vaginal intercourse with a demonstrably higher rate of infection, particularly in young women, researchers from the University of Pittsburgh report in the February issue of Sexually Transmitted Diseases, the journal of the American Sexually Transmitted Diseases Association.

28 Feb 2005

Virologists make major step towards understanding the process of HIV infection

A working group of virologists headed by Professor Hans-Georg Kräusslich at Heidelberg University Hospitals, jointly with Professor Hanswalter Zentgraf, Division of Applied Tumor Virology of the Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ), have been the first to label Human Immunodeficiency Viruses (HIV) for visual investigations without inhibiting the functional characteristics of the virus.

28 Feb 2005

New study following 12,574 individuals over the course of three years of HAART

Although clinical progression to AIDS of patients infected with Human immunodeficiency virus (HIV) has declined since the introduction of Highly Active Antiretroviral Therapy (HAART), there is little data on the changes in incidence of AIDS-defining events during the first few years of therapy.

28 Feb 2005

Youth with HIV take more risks after new meds introduced

Teens with HIV are having more risky sex with more partners than their counterparts did in the years before powerful new medications for HIV were introduced in 1996, according to a new report in the American Journal of Health Behavior.

28 Feb 2005

New compounds for the treatment of HIV/AIDS

Scientists from Tibotec Pharmaceuticals Ltd. presented data on several new compounds for the treatment of HIV/AIDS at the 12th Conference on Retroviruses and Opportunistic Infections (CROI), held February 22-25 in Boston, MA, USA.

27 Feb 2005

European approval of Pegasys for the treatment of chronic hepatitis B

The approval is granted for both types of the disease – HBeAg-positive and HBeAg-negative chronic hepatitis B. Pegasys offers the hope of a treatment-free life for thousands of people with chronic hepatitis B as this innovative drug has been shown to achieve lasting remission for a significant proportion of patients.

27 Feb 2005

New HIV screening method, nucleic acid amplification testing (NAAT)

Adding a new HIV screening method, called nucleic acid amplification testing (NAAT), to standard HIV testing, researchers were able to uncover six percent more cases of HIV infection in urban STD and drug treatment clinics and HIV testing sites in Atlanta than with standard HIV antibody tests alone.

27 Feb 2005

Importance of Fbw7 as an emerging tumor suppressor

The DNA tumor virus simian virus 40 produces the Large T antigen which inactivates two of the cell's most important cancer-preventing proteins, p53 and pRb.

27 Feb 2005

Gel provides protection from HIV and herpes

Mount Sinai School of Medicine researchers demonstrated that a gel applied in the vagina provides protection from both the human immunodeficiency virus (HIV) and the herpes simplex Virus. The study, presented at the 12th Conference on Retroviruses and Opportunistic Infections, is the first to show that a gel can retain anti-viral activity within the human vagina.

27 Feb 2005

Scientific rationale behind the use of antiretroviral therapy

Johns Hopkins researcher and infectious disease specialist Robert Siliciano, M.D., Ph.D., will provide an update on the scientific rationale behind the use of antiretroviral therapy, focusing on the mechanisms that allow life-long persistence of HIV even in patients on potent medication.

27 Feb 2005

Differences in how HIV virus infects males and females

A genetic analysis of viral RNA from 10 heterosexual couples, in which one partner has sexually transmitted HIV to the other, provides the first documentation of some differences in how the virus infects males and females.

27 Feb 2005

Pfizer acquires Idun Pharmaceuticals

Pfizer today announced that it has entered into an agreement to acquire Idun Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of therapies to control apoptosis, a process of cell death that occurs in a broad range of diseases.

24 Feb 2005

Control and containment key to combating avian influenza

Containing the bird flu virus to the greatest extent possible and reducing the risk of infection in poultry and farmed free-range ducks will help to prevent a global human influenza pandemic, the Food and Agriculture Organization (FAO) has announced.

24 Feb 2005

Herpesviruses are everywhere!

A population-based study of primary human herpesvirus 6 infection is reported in the current issue of the The New England Journal of Medicine (NEJM).

24 Feb 2005

Microsoft combs through millions of strains of human immunodeficiency virus (HIV)

Microsoft Research has pioneered promising new ways to combat one of humankind's most deadly viruses with advanced software typically used to analyze large computer databases and complex digital images, or to separate spam from legitimate e-mail.

23 Feb 2005

Need for greater understanding of shingles

Results from a recent international survey reveal that most people are aware of herpes zoster -- more commonly known as shingles -- but do not truly understand the complexity of the condition or the potential impact it has on their overall health.

23 Feb 2005

Association noted between certain non-lver cancers and hepatitis C

People infected with the hepatitis C virus (HCV) have a higher risk of developing non-Hodgkin's lymphoma and multiple myeloma, according to a recent study of the Swedish population.

22 Feb 2005

New information that may help guide design of vaccines for HIV-1

Scientists have uncovered new information that may help guide design of vaccines for HIV-1, the virus that causes AIDS. A new detailed structural analysis of the complex formed by an anti-HIV antibody called 4E10 and its specific target provides insight into why this particular antibody is so broadly effective, a rare characteristic for HIV discovered thus far.

22 Feb 2005

Antibody that neutralizes most HIV strains

A group of scientists from The Scripps Research Institute and several other institutions has solved the structure of a rare human antibody that broadly neutralizes human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS).

22 Feb 2005

Scientists have replicated hepatitis C virus (HCV) in the laboratory

For the first time, scientists have replicated hepatitis C virus (HCV) in the laboratory. The ability to replicate HCV in cell culture will allow researchers to better study the life cycle and biology of this virus and to test potential antiviral compounds, which may lead to new therapies for the liver disease that results from infection with HCV.

22 Feb 2005